Published in J Clin Immunol on March 01, 1999
The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. Adv Immunol (2010) 1.77
N-terminal RAG1 frameshift mutations in Omenn's syndrome: internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains. Proc Natl Acad Sci U S A (2000) 1.32
Mutations in conserved regions of the predicted RAG2 kelch repeats block initiation of V(D)J recombination and result in primary immunodeficiencies. Mol Cell Biol (2000) 1.20
Engraftment of human iPS cells and allogeneic porcine cells into pigs with inactivated RAG2 and accompanying severe combined immunodeficiency. Proc Natl Acad Sci U S A (2014) 1.07
Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome. J Exp Med (2010) 1.03
Analysis of mutations from SCID and Omenn syndrome patients reveals the central role of the Rag2 PHD domain in regulating V(D)J recombination. J Clin Invest (2010) 1.02
Genetics of SCID. Ital J Pediatr (2010) 1.02
Exome sequencing reveals RAG1 mutations in a child with autoimmunity and sterile chronic multifocal osteomyelitis evolving into disseminated granulomatous disease. J Clin Immunol (2013) 0.90
Single-cell transcriptional analysis of normal, aberrant, and malignant hematopoiesis in zebrafish. J Exp Med (2016) 0.85
An unusual concurrence of graft versus host disease caused by engraftment of maternal lymphocytes with DiGeorge anomaly. Arch Dis Child (2000) 0.84
Omenn's Syndrome: A rare primary immunodeficiency disorder. Sultan Qaboos Univ Med J (2007) 0.80
Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications. Blood (2012) 0.80
Compound heterozygous mutation of Rag1 leading to Omenn syndrome. PLoS One (2015) 0.75
The value of family history in diagnosing primary immunodeficiency disorders. Case Rep Pediatr (2014) 0.75
Somatic generation of antibody diversity. Nature (1983) 28.06
RAG-1-deficient mice have no mature B and T lymphocytes. Cell (1992) 20.97
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 19.80
RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell (1992) 17.50
The V(D)J recombination activating gene, RAG-1. Cell (1989) 9.79
RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science (1990) 9.33
Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature (1996) 6.23
IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity (1996) 6.16
Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell (1995) 5.58
Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system. Nature (1998) 5.47
Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature (1996) 5.45
Cleavage at a V(D)J recombination signal requires only RAG1 and RAG2 proteins and occurs in two steps. Cell (1995) 5.39
Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature (1997) 5.08
DNA transposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell (1998) 4.74
The mechanism of V(D)J joining: lessons from molecular, immunological, and comparative analyses. Adv Immunol (1994) 4.39
The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med (1995) 4.21
Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates. Cell (1996) 4.11
V(D)J recombination: a functional definition of the joining signals. Genes Dev (1989) 3.96
A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J recombination. Immunity (1998) 3.58
Growth retardation and leaky SCID phenotype of Ku70-deficient mice. Immunity (1997) 3.35
Partial V(D)J recombination activity leads to Omenn syndrome. Cell (1998) 3.18
RAG mutations in human B cell-negative SCID. Science (1996) 3.03
DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. Trends Biochem Sci (1995) 3.01
Initiation of V(D)J recombination in a cell-free system. Cell (1995) 3.00
Rch1, a protein that specifically interacts with the RAG-1 recombination-activating protein. Proc Natl Acad Sci U S A (1994) 2.86
Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci U S A (1996) 2.77
Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol (1996) 2.76
RAG1 and RAG2 form a stable postcleavage synaptic complex with DNA containing signal ends in V(D)J recombination. Cell (1997) 2.58
Targeted disruption of the catalytic subunit of the DNA-PK gene in mice confers severe combined immunodeficiency and radiosensitivity. Immunity (1998) 2.43
Expression and V(D)J recombination activity of mutated RAG-1 proteins. Nucleic Acids Res (1993) 2.39
A stable RAG1-RAG2-DNA complex that is active in V(D)J cleavage. Cell (1997) 2.37
The homeodomain region of Rag-1 reveals the parallel mechanisms of bacterial and V(D)J recombination. Cell (1996) 2.36
Stimulation of V(D)J cleavage by high mobility group proteins. EMBO J (1997) 2.35
Increased frequency of N-region insertion in a murine pre-B-cell line infected with a terminal deoxynucleotidyl transferase retroviral expression vector. Mol Cell Biol (1987) 2.33
RAG1 mediates signal sequence recognition and recruitment of RAG2 in V(D)J recombination. Cell (1996) 2.31
V(D)J recombination in Ku86-deficient mice: distinct effects on coding, signal, and hybrid joint formation. Immunity (1997) 2.10
Neoteny in lymphocytes: Rag1 and Rag2 expression in germinal center B cells. Science (1996) 2.03
Biochemical and genetic defects in the DNA-dependent protein kinase in murine scid lymphocytes. Mol Cell Biol (1996) 2.02
FAMILIAL RETICULOENDOTHELIOSIS WITH EOSINOPHILIA. N Engl J Med (1965) 2.02
Novel T-lymphocyte population in combined immunodeficiency with features of graft-versus-host disease. N Engl J Med (1989) 1.99
Reexpression of RAG-1 and RAG-2 genes in activated mature mouse B cells. Science (1996) 1.80
Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice. Proc Natl Acad Sci U S A (1997) 1.61
The lymph node pathology of Omenn's syndrome. Am J Surg Pathol (1995) 1.60
V(D)J recombination: modulation of RAG1 and RAG2 cleavage activity on 12/23 substrates by whole cell extract and DNA-bending proteins. J Exp Med (1997) 1.59
Conservation of sequence in recombination signal sequence spacers. Nucleic Acids Res (1994) 1.58
Hairpin coding end opening is mediated by RAG1 and RAG2 proteins. Mol Cell (1998) 1.44
Complementation of V(D)J recombination deficiency in RAG-1(-/-) B cells reveals a requirement for novel elements in the N-terminus of RAG-1. Immunity (1997) 1.37
Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). J Clin Invest (1991) 1.36
Localization, interaction, and RNA binding properties of the V(D)J recombination-activating proteins RAG1 and RAG2. Immunity (1995) 1.34
CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur J Immunol (1996) 1.33
Identification by HLA typing of intrauterine-derived maternal T cells in four patients with severe combined immunodeficiency. N Engl J Med (1982) 1.30
The cell cycle and V(D)J recombination. Curr Top Microbiol Immunol (1996) 1.27
A human severe combined immunodeficiency (SCID) condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J Exp Med (1998) 1.24
A basic motif in the N-terminal region of RAG1 enhances V(D)J recombination activity. Mol Cell Biol (1997) 1.15
Highly restricted human T cell repertoire in peripheral blood and tissue-infiltrating lymphocytes in Omenn's syndrome. J Clin Invest (1998) 1.13
Mechanism of V(D)J recombination. Curr Opin Immunol (1996) 1.13
Primordial emergence of the recombination activating gene 1 (RAG1): sequence of the complete shark gene indicates homology to microbial integrases. Proc Natl Acad Sci U S A (1996) 1.11
Combined immunodeficiency and reticuloendotheliosis with eosinophilia. J Pediatr (1974) 1.08
Sequence of the spacer in the recombination signal sequence affects V(D)J rearrangement frequency and correlates with nonrandom Vkappa usage in vivo. J Exp Med (1998) 1.04
Definition of a large region of RAG1 that is important for coimmunoprecipitation of RAG2. J Immunol (1997) 1.03
T helper type 2-like cells and therapeutic effects of interferon-gamma in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). Eur J Immunol (1993) 1.00
Increased radiosensitivity of granulocyte macrophage colony-forming units and skin fibroblasts in human autosomal recessive severe combined immunodeficiency. J Clin Invest (1993) 1.00
Oligoclonal expansion of CD45RO+ T lymphocytes in Omenn syndrome. J Clin Immunol (1997) 0.94
Cloning and characterization of the human recombination activating gene 1 (RAG1) and RAG2 promoter regions. J Immunol (1997) 0.92
In vitro cell death of activated lymphocytes in Omenn's syndrome. Eur J Immunol (1997) 0.91
The recombination activating genes, RAG 1 and RAG 2, are on chromosome 11p in humans and chromosome 2p in mice. Immunogenetics (1992) 0.91
[Severe combined immune deficiency with hypereosinophilia. Immunologic study of 5 cases]. Arch Fr Pediatr (1985) 0.86
Treatment of Omenn syndrome by bone marrow transplantation. J Pediatr (1995) 0.85
Graft vs graft reaction resulting in the elimination of maternal cells in a SCID patient with maternofetal GVHd after an HLA identical bone marrow transplantation. J Immunol (1987) 0.80
The pathology of Omenn's syndrome. Am J Surg Pathol (1996) 0.76
Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell (2000) 9.99
Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol (1999) 5.98
Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature (1993) 4.39
Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr (1997) 3.63
Partial V(D)J recombination activity leads to Omenn syndrome. Cell (1998) 3.18
Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet (2000) 3.12
FokI requires two specific DNA sites for cleavage. J Mol Biol (2001) 2.83
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science (1995) 2.79
V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood (2001) 2.50
Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A (2001) 2.39
The homeodomain region of Rag-1 reveals the parallel mechanisms of bacterial and V(D)J recombination. Cell (1996) 2.36
Studies of the expression of the Wiskott-Aldrich syndrome protein. J Clin Invest (1996) 1.87
Implication of tubby proteins as transcription factors by structure-based functional analysis. Science (1999) 1.64
The RAG1 homeodomain recruits HMG1 and HMG2 to facilitate recombination signal sequence binding and to enhance the intrinsic DNA-bending activity of RAG1-RAG2. Mol Cell Biol (1999) 1.61
Restricted expression of T cell receptor V beta but not V alpha genes in rheumatoid arthritis. Eur J Immunol (1991) 1.55
Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family. Clin Immunol (2001) 1.44
Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol (2000) 1.38
Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. J Immunol (1998) 1.37
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV. J Infect Dis (1997) 1.35
What is metamorphosis? Integr Comp Biol (2006) 1.35
The RAG1/RAG2 complex constitutes a 3' flap endonuclease: implications for junctional diversity in V(D)J and transpositional recombination. Mol Cell (1999) 1.35
In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI). Lancet (1996) 1.35
Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood (1997) 1.34
CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur J Immunol (1996) 1.33
N-terminal RAG1 frameshift mutations in Omenn's syndrome: internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains. Proc Natl Acad Sci U S A (2000) 1.32
Defective expression of CD40 ligand on T cells causes "X-linked immunodeficiency with hyper-IgM (HIGM1)". Immunol Rev (1994) 1.32
Immunology of Down syndrome: a review. Am J Med Genet Suppl (1990) 1.30
The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet (2001) 1.29
Intrathymic restriction and peripheral expansion of the T-cell repertoire in Omenn syndrome. Blood (1999) 1.27
Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol (2011) 1.24
Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood (1997) 1.23
Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol (2001) 1.23
Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. Am J Pathol (1999) 1.21
Mutations in conserved regions of the predicted RAG2 kelch repeats block initiation of V(D)J recombination and result in primary immunodeficiencies. Mol Cell Biol (2000) 1.20
Novel Munc13-4 mutations in children and young adult patients with haemophagocytic lymphohistiocytosis. J Med Genet (2006) 1.20
Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol (2013) 1.16
Inhibiting HSP90 to treat cancer: a strategy in evolution. Curr Mol Med (2012) 1.14
Definition of minimal domains of interaction within the recombination-activating genes 1 and 2 recombinase complex. J Immunol (2000) 1.14
Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity (1996) 1.13
Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther (2004) 1.13
A novel 4-kb interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4/interleukin-13 receptor. Eur J Immunol (1997) 1.08
Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis. J Clin Invest (1985) 1.08
Six novel mutations in the PRF1 gene in children with haemophagocytic lymphohistiocytosis. J Med Genet (2001) 1.07
X-chromosome inactivation analysis in a female carrier of FOXP3 mutation. Clin Exp Immunol (2002) 1.06
Unexpected and variable phenotypes in a family with JAK3 deficiency. Genes Immun (2001) 1.05
Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood (1997) 1.04
IgM and IgD concentrations in the serum and secretions of children with selective IgA deficiency. Clin Exp Immunol (1983) 1.03
BTKbase: a database of XLA-causing mutations. International Study Group. Immunol Today (1995) 1.03
CD70 expression on T-cell subpopulations: study of normal individuals and patients with chronic immune activation. Immunol Lett (1997) 1.02
PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun (2010) 1.01
CD40lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome. Immunol Today (1996) 1.00
Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency. Clin Immunol (2000) 0.98
Organization of the human CD40L gene: implications for molecular defects in X chromosome-linked hyper-IgM syndrome and prenatal diagnosis. Proc Natl Acad Sci U S A (1994) 0.98
Defective actin polymerization in EBV-transformed B-cell lines from patients with the Wiskott-Aldrich syndrome. J Pathol (1998) 0.98
Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease. Proc Natl Acad Sci U S A (1994) 0.97
Different TCRBV genes generate biased patterns of V-D-J diversity in human T cells. Immunogenetics (1995) 0.96
The spleen in the Wiskott-Aldrich syndrome: histopathologic abnormalities of the white pulp correlate with the clinical phenotype of the disease. Am J Surg Pathol (1999) 0.96
Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant (2006) 0.96
Primary immunodeficiency mutation databases. Adv Genet (2001) 0.95
Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol (2012) 0.94
Linker for activation of T cells (LAT), a novel immunohistochemical marker for T cells, NK cells, mast cells, and megakaryocytes: evaluation in normal and pathological conditions. Am J Pathol (1999) 0.93
Enhanced interleukin 1 and depressed interleukin 2 production in juvenile arthritis. J Rheumatol (1986) 0.93
Close linkage of probe p212 (DXS178) to X-linked agammaglobulinemia. Hum Genet (1989) 0.92
A PCR-based non-radioactive X-chromosome inactivation assay for genetic counseling in X-linked primary immunodeficiencies. Life Sci (1997) 0.92
Isolation, purification, and heterogeneity of human lymphatic endothelial cells from different tissues. Lymphology (2005) 0.91
High prevalence of nonsense, frame shift, and splice-site mutations in 16 patients with full-blown Wiskott-Aldrich syndrome. Blood (1995) 0.91
In vitro cell death of activated lymphocytes in Omenn's syndrome. Eur J Immunol (1997) 0.91
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clin Cancer Res (2013) 0.91
Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). J Pathol (2009) 0.91
The hyper-IgM (HIM) syndrome. Springer Semin Immunopathol (1998) 0.90
Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome. Cancer Gene Ther (2000) 0.89
Defective expression of HLA class I and CD1a molecules in boy with Marfan-like phenotype and deep skin ulcers. J Am Acad Dermatol (1996) 0.89
Reduction of peripheral blood T cells producing IFN-γ and IL-17 after therapy with abatacept for rheumatoid arthritis. Clin Exp Rheumatol (2014) 0.89
IgG subclass serum levels in juvenile chronic arthritis. Ann Rheum Dis (1986) 0.89
Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children. J Clin Endocrinol Metab (2006) 0.88
Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. J Clin Immunol (1997) 0.88
Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen. Cancer Res (1987) 0.88
Activity of classical and alternative pathways of complement in preterm and small for gestational age infants. Pediatr Res (1984) 0.88
B cell function after haploidentical in utero bone marrow transplantation in a patient with severe combined immunodeficiency. Bone Marrow Transplant (2002) 0.88
Presentation of Wiskott Aldrich syndrome as isolated thrombocytopenia. Blood (1991) 0.88
A new case of IPEX receiving bone marrow transplantation. Bone Marrow Transplant (2005) 0.87
Pregnancy in a methylmalonic acidemia patient with kidney transplantation: a case report. Am J Transplant (2013) 0.87
Immunochemical analysis of the modulation of human melanoma-associated antigens by DNA recombinant immune interferon. J Immunol (1985) 0.87
Effect of Cyclosporin A on prostacyclin synthesis by vascular tissue. Thromb Res (1983) 0.86
Characterization of a CD38-like 78-kilodalton soluble protein released from B cell lines derived from patients with X-linked agammaglobulinemia. J Clin Invest (1998) 0.86
Unbalanced plasma control of TxA2 and PGI2 synthesis in vitamin E-deficient rats. Am J Physiol (1983) 0.86